Compositions and methods for treating diabetic cardiomyopathy
AssigneeUniversity of Utah Research Foundation
InventorsTingTing HONG, Robin M. SHAW, Jing LI
Life of this patent
Estimating the term…
Abstract
Described herein are compositions and methods for treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of a medical condition related to diabetic cardiomyopathy in a subject using cardiac bridging integrator 1 (cBIN1) as a therapeutic agent. In one embodiment, the compositions and methods comprise a cBIN1 gene therapy. In another embodiment, the disclosed compositions and methods may reduce blood glucose levels in a subject.
Claims38
A method of treating, preventing, reducing the likelihood of having, reducing the severity of, and/or slowing the progression of diabetic cardiomyopathy in a subject, the method comprising:
- administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising:
- a cardiac bridging integrator 1 (cBIN1) gene expression vector comprising a cBIN1 polynucleotide sequence encoding a cBIN1 polypeptide or functional variant or fragment thereof.
A pharmaceutical composition comprising a cardiac bridging integrator 1 (cBIN1) gene expression vector comprising a cBIN1 polynucleotide sequence encoding a cBIN1 polypeptide or functional variant or fragment thereof.
Use of a cardiac bridging integrator 1 (cBIN1) gene therapy in a medicament for treating, preventing, reducing the likelihood of having, reducing the severity of, and/or slowing the progression of diabetic cardiomyopathy in a subject.
Use of a plasma cardiac bridging integrator 1 (cBIN1) score (CS) to identify a subject having diabetic cardiomyopathy for cBIN1 gene therapy treatment.
Dependencies are inferred from the claim text.